All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View GvHD content recommended for you
Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used to treat acute and chronic graft-versus-host disease (GvHD), particularly in the setting of steroid-refractory (SR) GvHD, due to its immunomodulatory mechanism of action, favorable safety profile, and steroid-sparing efficacy.1–3
The GvHD Hub spoke with Daniel Wolff, Hildegard Greinix, and Robert Zeiser to gain their expert insights into the role of ECP for the treatment of SR-GvHD, including unmet needs, key clinical considerations for ECP use, and how it should be positioned in the evolving GvHD treatment landscape.
The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What are the key clinical considerations for the use of ECP in steroid-refractory GvHD?
The GvHD Hub spoke with Hildegard Greinix, Medical University of Vienna, Vienna, AT. We asked, What are the ongoing unmet needs in SR-GvHD, and how can ECP potentially address these?
The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How can ECP be positioned in the current GvHD treatment landscape as a steroid-free intervention?
This educational resource is independently supported by Therakos. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Robert Zeiser
Hildegard Greinix
Daniel Wolff
